AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
cidofovir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals phosphonic acid derivatives | 639 | 113852-37-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 25 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 170 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 90 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 17.91 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 5 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.49 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.60 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ULK1,ZAP70 | 52 | |||
| kinase-selectivity-class | AXL,BRAF,CDK4,CDK9,EPHB4,ERBB2,GRK2,IRAK3,MAP2K6,MAP3K14,MAPK7,PIK3CD,PRKDC,SYK,TEK,TGFBR1,ZAP70 | 17 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 26, 1996 | FDA | GILEAD SCIENCES INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Adenovirus infection | 220.95 | 73.60 | 44 | 2076 | 4578 | 90621749 |
| Viral haemorrhagic cystitis | 186.53 | 73.60 | 32 | 2088 | 1461 | 90624866 |
| Drug resistance | 176.77 | 73.60 | 53 | 2067 | 30396 | 90595931 |
| Cytomegalovirus infection reactivation | 108.27 | 73.60 | 27 | 2093 | 7773 | 90618554 |
| Nephropathy toxic | 104.37 | 73.60 | 29 | 2091 | 12659 | 90613668 |
| Hypouricaemia | 94.22 | 73.60 | 14 | 2106 | 250 | 90626077 |
| Cystitis haemorrhagic | 91.31 | 73.60 | 22 | 2098 | 5491 | 90620836 |
| BK virus infection | 90.43 | 73.60 | 21 | 2099 | 4477 | 90621850 |
| Acidosis hyperchloraemic | 83.51 | 73.60 | 15 | 2105 | 891 | 90625436 |
| Off label use | 81.60 | 73.60 | 113 | 2007 | 1102139 | 89524188 |
| Immune reconstitution inflammatory syndrome | 76.31 | 73.60 | 20 | 2100 | 6999 | 90619328 |
| Epstein-Barr virus infection reactivation | 74.65 | 73.60 | 15 | 2105 | 1622 | 90624705 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug resistance | 163.06 | 46.15 | 60 | 1829 | 34188 | 42585258 |
| Cystitis haemorrhagic | 134.15 | 46.15 | 36 | 1853 | 7293 | 42612153 |
| Off label use | 110.64 | 46.15 | 137 | 1752 | 638198 | 41981248 |
| Adenovirus infection | 99.35 | 46.15 | 28 | 1861 | 6781 | 42612665 |
| Drug ineffective | 80.69 | 46.15 | 117 | 1772 | 630080 | 41989366 |
| Drug ineffective for unapproved indication | 72.49 | 46.15 | 37 | 1852 | 46126 | 42573320 |
| Pathogen resistance | 54.09 | 46.15 | 20 | 1869 | 11430 | 42608016 |
| Nephropathy toxic | 53.31 | 46.15 | 22 | 1867 | 16816 | 42602630 |
| JC virus infection | 51.36 | 46.15 | 14 | 1875 | 2990 | 42616456 |
| Cytomegalovirus infection | 50.97 | 46.15 | 26 | 1863 | 32280 | 42587166 |
| Cytomegalovirus viraemia | 48.55 | 46.15 | 18 | 1871 | 10359 | 42609087 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug resistance | 336.16 | 54.57 | 111 | 3891 | 56263 | 110529034 |
| Adenovirus infection | 267.17 | 54.57 | 65 | 3937 | 10929 | 110574368 |
| Cystitis haemorrhagic | 215.99 | 54.57 | 56 | 3946 | 12153 | 110573144 |
| Off label use | 178.52 | 54.57 | 242 | 3760 | 1499943 | 109085354 |
| Nephropathy toxic | 155.08 | 54.57 | 52 | 3950 | 27426 | 110557871 |
| Viral haemorrhagic cystitis | 151.80 | 54.57 | 33 | 3969 | 3366 | 110581931 |
| Drug ineffective | 146.27 | 54.57 | 222 | 3780 | 1520318 | 109064979 |
| Cytomegalovirus infection reactivation | 141.46 | 54.57 | 44 | 3958 | 18289 | 110567008 |
| Pathogen resistance | 138.82 | 54.57 | 43 | 3959 | 17629 | 110567668 |
| BK virus infection | 138.06 | 54.57 | 40 | 3962 | 13066 | 110572231 |
| Cytomegalovirus infection | 117.21 | 54.57 | 51 | 3951 | 54393 | 110530904 |
| Epstein-Barr virus infection reactivation | 113.85 | 54.57 | 27 | 3975 | 4057 | 110581240 |
| Immune reconstitution inflammatory syndrome | 108.81 | 54.57 | 35 | 3967 | 16191 | 110569106 |
| Renal impairment | 105.05 | 54.57 | 72 | 3930 | 188373 | 110396924 |
| Cytomegalovirus viraemia | 93.81 | 54.57 | 32 | 3970 | 17732 | 110567565 |
| Acute kidney injury | 82.97 | 54.57 | 108 | 3894 | 635322 | 109949975 |
| Hypouricaemia | 77.13 | 54.57 | 14 | 3988 | 564 | 110584733 |
| Drug ineffective for unapproved indication | 76.15 | 54.57 | 47 | 3955 | 102791 | 110482506 |
| Polyomavirus-associated nephropathy | 73.08 | 54.57 | 22 | 3980 | 8179 | 110577118 |
| Acidosis hyperchloraemic | 68.57 | 54.57 | 15 | 3987 | 1571 | 110583726 |
| Herpes simplex | 62.66 | 54.57 | 23 | 3979 | 15741 | 110569556 |
| Bladder hypertrophy | 62.03 | 54.57 | 13 | 3989 | 1111 | 110584186 |
| Renal tubular injury | 58.54 | 54.57 | 15 | 3987 | 3093 | 110582204 |
| Polyomavirus viraemia | 56.88 | 54.57 | 15 | 3987 | 3459 | 110581838 |
| Human herpesvirus 6 infection | 55.83 | 54.57 | 17 | 3985 | 6564 | 110578733 |
| Multiple organ dysfunction syndrome | 55.35 | 54.57 | 45 | 3957 | 151665 | 110433632 |
| Acute graft versus host disease in skin | 55.33 | 54.57 | 19 | 3983 | 10721 | 110574576 |
| Adenovirus reactivation | 55.24 | 54.57 | 11 | 3991 | 729 | 110584568 |
| JC virus infection | 55.04 | 54.57 | 16 | 3986 | 5274 | 110580023 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AB12 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Nucleosides and nucleotides excl. reverse transcriptase inhibitors |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:36044 | antiviral drug |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
Related Drugs by ATC class:
J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| CMV Retinitis in AIDS Patients | indication | ||
| Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients | indication | ||
| Prevention of Cytomegalovirus Disease | off-label use | ||
| Acidosis | contraindication | 51387008 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Severe Chronic Neutropenia | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.81 | acidic |
| pKa2 | 12.99 | acidic |
| pKa3 | 4.1 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| DNA polymerase catalytic subunit | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020976 | VUID |
| N0000148447 | NUI |
| D00273 | KEGG_DRUG |
| 83170 | RXNORM |
| C0286079 | UMLSCUI |
| CHEBI:3696 | CHEBI |
| L8P | PDB_CHEM_ID |
| CHEMBL5314375 | ChEMBL_ID |
| DB00369 | DRUGBANK_ID |
| D000077404 | MESH_DESCRIPTOR_UI |
| 60613 | PUBCHEM_CID |
| JIL713Q00N | UNII |
| 194597 | MMSL |
| 4446 | MMSL |
| 6016 | MMSL |
| d04028 | MMSL |
| 006053 | NDDF |
| 108688007 | SNOMEDCT_US |
| 278161000202101 | SNOMEDCT_US |
| 386894007 | SNOMEDCT_US |
| CHEMBL152 | ChEMBL_ID |
| 149394-66-1 | SECONDARY_CAS_RN |
| 4020976 | VANDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| CIDOFOVIR DIHYDRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-216 | INJECTION, SOLUTION | 375 mg | INTRAVENOUS | ANDA | 21 sections |
| Vistide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61958-0101 | INJECTION | 75 mg | INTRAVENOUS | NDA | 24 sections |
| CIDOFOVIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-210 | INJECTION, SOLUTION | 75 mg | INTRAVENOUS | ANDA | 26 sections |